Bristol-Myers Squibb Company vs ELI LILLY & Co, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and LLY diverge most: on ev/ebitda, BMY reads 45.6 and LLY reads 2180.2; on revenue growth, BMY reads +1.8% and LLY reads +47.4%. The rest of the comparable metrics sit closer together. What BMY's price implies is a bet that sits within the historical range (whole-company basis). What LLY's price implies is a demanding bet versus history and the cohort (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BMY | LLY |
|---|---|---|
| Price | $62.09 | $1196.14 |
| Market cap | $127.1B | $1.07T |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +26.7% |
| P/E | 17.4 | 42.5 |
| P/B | 6.32 | 34.35 |
| P/S | 2.62 | 14.83 |
| EV/EBITDA | 45.6 | 2180.2 |
| Revenue growth | +1.8% | +47.4% |
| Net margin | 15.0% | 35.0% |
| Return on equity | 36.2% | 81.0% |
| Return on assets | 8.4% | 21.7% |
| FCF yield | 9.4% | 1.9% |
| Dividend yield | 4.0% | 0.5% |
| Debt / equity | 2.31 | 1.39 |
| Current ratio | 1.42 | 1.50 |
| Altman Z (solvency) | 2.12 | 7.16 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.